Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.

ABSTRACT:

Objective

To assess the pharmacokinetics and pharmacodynamics of the long-acting terminal complement 5 (C5) inhibitor ravulizumab in adults with anti-aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) in the phase 3, open-label CHAMPION-NMOSD trial (NCT04201262).

Methods

Patients aged 18 years or older received a weight-based intravenous loading dose of ravulizumab (2,400-3,000 mg) on day 1, followed by weight-based maintenance doses (3,000-3,600 mg) on day 15 and once every 8 weeks thereafter. Pharmacokinetic assessments were maximum observed concentration (C_max, assessed at the end of the infusion) and concentration at the end of the dosing interval (C_trough, assessed before dosing) for ravulizumab. Phar

SUBMITTER: Ortiz S 

PROVIDER: S-EPMC10865503 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature